Name: KPTI: Karyopharm Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir shares are surging as the company reported a massive earnings beat, driven by explosive demand for its AI software within both government and U.S. commercial sectors. The community is actively debating the stock's long-term potential and valuation, with many bulls celebrating the crushing of bear theses while some caution that the rapid post-earnings rally could lead to short-term volatility.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors focus on the upcoming August 5th launch of its BlueBird satellites and anticipation surrounding the Q2 earnings release. The community remains highly focused on the company's deepening commercial partnerships, regulatory approvals for direct-to-cell services, and the potential impact of high short interest on the stock's volatility.

Anthropic

Anthropic is actively navigating heightened regulatory scrutiny, including recent export controls and cybersecurity investigations, while investors closely monitor its potential IPO plans and heavy infrastructure expansion. The community remains divided, weighing the long-term potential of its advanced Claude models against ongoing concerns over high capital expenditures and intense competitive pressure from other major AI developers.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify Technology S.A. ($SPOT) is trending as investors and analysts weigh its long-term growth potential and AI-driven product strategy ahead of upcoming earnings, with active discussions focused on whether the stock can maintain its upward momentum amid shifting sector sentiment. Community chatter highlights a divide between those betting on the company's profitability inflection and those concerned about valuation, with many traders closely monitoring technical support levels and institutional activity.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is generating intense market activity as investors weigh its first public earnings report against a massive upcoming lock-up expiration that threatens to flood the market with nearly one billion shares. The community remains deeply divided, with bulls betting on an Elon Musk-led breakout and potential short squeeze, while bears argue that persistent cash burn and the looming supply surge make the current valuation unsustainable.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending as investors scrutinize the company's crucial role in data center infrastructure, with the community actively debating whether current valuation premiums are justified by ongoing AI-driven demand. The discussion centers on whether the stock can maintain its momentum amid mixed analyst sentiment, regulatory hurdles for data center construction, and broader concerns regarding AI infrastructure spending cycles.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently trending as the community debates whether the token's recent price action signals a genuine breakout or a liquidity trap, fueled by intense discussions around its fee-burning mechanics and role in the decentralized perpetual exchange space. Traders are closely monitoring the token's structural distribution phase, with active debates centered on whether recent volatility represents a massive opportunity for long-term accumulation or a warning sign of further downward pressure.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil is seeing heightened attention as traders react to persistent volatility in the Strait of Hormuz and ongoing speculation surrounding potential Iranian production negotiations. While many in the community are analyzing the impact of geopolitical escalations and energy infrastructure supply risks, others are closely tracking the ETF's daily reset dynamics as they navigate the sharp price swings in crude oil.

OpenAI

OpenAI is dominating market conversation as the company moves toward a highly anticipated IPO while navigating intense scrutiny over its governance, competitive pricing strategies, and security incidents involving agentic models. The community remains divided, with some investors betting on explosive long-term growth through its massive infrastructure projects, while critics question the sustainability of the company's capital-intensive business model and the legitimacy of its recent board-level changes.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community buzz as investors eagerly await Phase 3 IZAR-1 trial results, with many anticipating a significant catalyst that could trigger a re-rating of the stock. While participants are actively debating the timing of the readout and the potential for a strategic acquisition, the discourse remains heavily focused on the clinical data's ability to demonstrate best-in-class efficacy for inflammatory diseases.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Aug. 3, 2026 NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Why Is KPTI Stock Down 69% After-Hours Today?

Equity

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. 


Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PR Newswire NEWTON, Mass., July 30, 2026 Company Plans to Submit sNDA...

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PR Newswire NEWTON, Mass., July 30, 2026 The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026...

Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +21.96% and +4.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., July 1, 2026 NEWTON, Mass., July 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PR Newswire NEWTON, Mass., June 3, 2026 NEWTON, Mass., June 3, 2026 /PRNewswire/ -- Karyopharm...

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PR Newswire NEWTON...

$KPTI Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.02 up 63.18% YoY
• Reported revenue of $35.07M up 16.83% YoY
• Karyopharm reaffirms full-year 2026 total revenue guidance of $130 million to $150 million, including U.S. XPOVIO net product revenue of $115 million to $130 million for Karyopharm.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPTIKaryopharm Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest KPTI News